Baris Gencer1, Reto Auer2, Nathalie de Rekeneire3, Javed Butler4, Andreas Kalogeropoulos5, Douglas C Bauer6, Stephen B Kritchevsky7, Iva Miljkovic8, Eric Vittinghoff9, Tamara Harris10, Nicolas Rodondi11. 1. Cardiology Division, Department of Medicine, Geneva University Hospital, Switzerland. 2. Department of Ambulatory and Community Medicine, Lausanne University Hospital, Switzerland. 3. Geriatric Section, Department of Internal Medicine, Yale University, New Haven, CT, USA. 4. Division of Cardiology, Stony Brook University, Long Island, New York, USA. 5. Cardiology Division, Emory University, Atlanta, GA, USA. 6. Department of Medicine, University of California, San Francisco, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, USA. 7. Sticht Center on Aging, Wake Forrest School of Medicine, Winston-Salem, North Carolina, USA. 8. Center for Aging and Population Health, Department of Epidemiology, University of Pittsburgh, Pennsylvania, USA. 9. Department of Medicine, University of California, San Francisco, USA. 10. Geriatric Epidemiology Section, National Institute on Aging, Bethesda, MD, USA. 11. Department of General Internal Medicine, Bern University Hospital, Switzerland. Electronic address: Nicolas.Rodondi@insel.ch.
Abstract
OBJECTIVE: Prospective data on the association between resistin levels and cardiovascular disease (CVD) events are sparse with conflicting results. METHODS: We studied 3044 aged 70-79 years from the Health, Aging, and Body Composition Study. CVD events were defined as coronary heart disease (CHD) or stroke events. «Hard » CHD events were defined as CHD death or myocardial infarction. We estimated hazard ratio (HR) and 95% confidence intervals (CI) according to the quartiles of serum resistin concentrations and adjusted for clinical variables, and then further adjusted for metabolic disease (body mass index, fasting plasma glucose, abdominal visceral and subcutaneous adipose tissue, leptin, adiponectin, insulin) and inflammation (C-reactive protein, interleukin-6, tumor necrosis factors-α). RESULTS: During a median follow-up of 10.1 years, 559 patients had « hard » CHD events, 884 CHD events and 1106 CVD Events. Unadjusted incidence rate for CVD events was 36.6 (95% CI 32.1-41.1) per 1000 persons-year in the lowest quartile and 54.0 per 1000 persons-year in the highest quartile (95% CI 48.2-59.8, P for trend < 0.001). In the multivariate models adjusted for clinical variables, HRs for the highest vs. lowest quartile of resistin was 1.52 (95% CI 1.20-1.93, P < 0.001) for « Hard » CHD events, 1.41 (95% CI 1.16-1.70, P = 0.001) for CHD events and 1.35 (95% CI 1.14-1.59, P = 0.002) for CVD events. Further adjustment for metabolic disease slightly reduced the associations while adjustment for inflammation markedly reduced the associations. CONCLUSIONS: In older adults, higher resistin levels are associated with CVD events independently of clinical risk factors and metabolic disease markers, but markedly attenuated by inflammation.
OBJECTIVE: Prospective data on the association between resistin levels and cardiovascular disease (CVD) events are sparse with conflicting results. METHODS: We studied 3044 aged 70-79 years from the Health, Aging, and Body Composition Study. CVD events were defined as coronary heart disease (CHD) or stroke events. «Hard » CHD events were defined as CHD death or myocardial infarction. We estimated hazard ratio (HR) and 95% confidence intervals (CI) according to the quartiles of serum resistin concentrations and adjusted for clinical variables, and then further adjusted for metabolic disease (body mass index, fasting plasma glucose, abdominal visceral and subcutaneous adipose tissue, leptin, adiponectin, insulin) and inflammation (C-reactive protein, interleukin-6, tumor necrosis factors-α). RESULTS: During a median follow-up of 10.1 years, 559 patients had « hard » CHD events, 884 CHD events and 1106 CVD Events. Unadjusted incidence rate for CVD events was 36.6 (95% CI 32.1-41.1) per 1000 persons-year in the lowest quartile and 54.0 per 1000 persons-year in the highest quartile (95% CI 48.2-59.8, P for trend < 0.001). In the multivariate models adjusted for clinical variables, HRs for the highest vs. lowest quartile of resistin was 1.52 (95% CI 1.20-1.93, P < 0.001) for « Hard » CHD events, 1.41 (95% CI 1.16-1.70, P = 0.001) for CHD events and 1.35 (95% CI 1.14-1.59, P = 0.002) for CVD events. Further adjustment for metabolic disease slightly reduced the associations while adjustment for inflammation markedly reduced the associations. CONCLUSIONS: In older adults, higher resistin levels are associated with CVD events independently of clinical risk factors and metabolic disease markers, but markedly attenuated by inflammation.
Authors: Evan D Muse; David I Feldman; Michael J Blaha; Zeina A Dardari; Roger S Blumenthal; Matthew J Budoff; Khurram Nasir; Michael H Criqui; Mary Cushman; Robyn L McClelland; Matthew A Allison Journal: Atherosclerosis Date: 2014-12-23 Impact factor: 5.162
Authors: Mary Susan Burnett; Joseph M Devaney; Remi J Adenika; Robert Lindsay; Barbara V Howard Journal: J Clin Endocrinol Metab Date: 2005-10-25 Impact factor: 5.958
Authors: Qibin Qi; Claudia Menzaghi; Shelly Smith; Liming Liang; Nathalie de Rekeneire; Melissa E Garcia; Kurt K Lohman; Iva Miljkovic; Elsa S Strotmeyer; Steve R Cummings; Alka M Kanaya; Frances A Tylavsky; Suzanne Satterfield; Jingzhong Ding; Eric B Rimm; Vincenzo Trischitta; Frank B Hu; Yongmei Liu; Lu Qi Journal: Hum Mol Genet Date: 2012-07-26 Impact factor: 6.150
Authors: Rong-Ze Yang; Qing Huang; Aihua Xu; John C McLenithan; Jonathan A Eisen; Alan R Shuldiner; Serhan Alkan; Da-Wei Gong; Jonathan A Eison Journal: Biochem Biophys Res Commun Date: 2003-10-24 Impact factor: 3.575
Authors: Subodh Verma; Shu-Hong Li; Chao-Hung Wang; Paul W M Fedak; Ren-Ke Li; Richard D Weisel; Donald A G Mickle Journal: Circulation Date: 2003-07-21 Impact factor: 29.690
Authors: Kristine Yaffe; Cherie M Falvey; Nathan Hamilton; Tamara B Harris; Eleanor M Simonsick; Elsa S Strotmeyer; Ronald I Shorr; Andrea Metti; Ann V Schwartz Journal: JAMA Intern Med Date: 2013-07-22 Impact factor: 21.873
Authors: Greg J Zahner; Joel L Ramirez; Kimberly A Spaulding; Sukaynah A Khetani; Warren J Gasper; Carl Grunfeld; Nancy K Hills; Anne L Schafer; S Marlene Grenon Journal: J Surg Res Date: 2019-02-06 Impact factor: 2.192
Authors: Joel L Ramirez; Sukaynah A Khetani; Greg J Zahner; Kimberly A Spaulding; Melinda S Schaller; Warren J Gasper; Nancy K Hills; Anne L Schafer; S Marlene Grenon Journal: J Vasc Surg Date: 2018-10-03 Impact factor: 4.268